Citi downgrades Eli Lilly to Neutral after 40% of sector outperformance

Citi analyst Andrew Baum downgraded Eli Lilly to Neutral from Buy while raising his price target for the shares to $115 from $96. The stock closed Friday up 64c to $112.87. After 40% of outperformance versus the sector over the last 10 months, the stock is now trading close to estimated net present value, Baum tells investors in a research note. The analyst believes forecasts for Lilly’s in-market drugs, pipeline, portfolio restructuring and spending tightening are now increasingly priced into the valuation. Further, he struggles to find “material near term upside from current levels.”
https://thefly.com/landingPageNews.php?id=2827631